Please login to the form below

Not currently logged in
Email:
Password:

neurodegeneration

This page shows the latest neurodegeneration news and features for those working in and with pharma, biotech and healthcare.

Merck acquires pre-clinical biotech Calporta for up to $576m

Merck acquires pre-clinical biotech Calporta for up to $576m

Expands into early-stage neurodegeneration research field. Merck has taken a stake in the neurodegeneration research field, following the acquisition of San-Diego, US-based Calporta. .

Latest news

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics